Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications;Využití stanovení agregability trombocytů po indukci kationickým propylgalátem v odhadu recidiv kardiovaskulárních komplikací

Vnitrni Lekarstvi

Volumn 50, Issue 8, 2004, Pages 591-599

  Stejskal, David ^a,d   Proskova J ^a   Lacnak B ^b   Horalik D ^b   Hamplova A ^b   Oral, I ^c   Hrabovska I ^a   Ochmanova R ^b   Adamovska S ^a   Jurakova R ^a   Ozanova G ^b   Juchelka, J ^b   Kuliskova O ^b   Penkavova H ^b  

^a Oddeleni Lab Mediciny Nemocnice   (Czech Republic)

^b Interni Oddeleni Nemocnice   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^d NONE   (Czech Republic)

Author keywords

Acute coronary syndrome; Aggregation of thrombocytes; Aggregometers; ASA resistance; CPG

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATIONIC PROPYL GALLATE; CHOLESTEROL; COUMARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALLIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; STATINE DERIVATIVE; TICLOPIDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; GALLIC ACID PROPYL ESTER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESISTANCE; HOMEOSTASIS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; RECURRENCE RISK; RECURRENT DISEASE; RISK FACTOR; SMOKING; ST SEGMENT ELEVATION; THROMBOCYTE AGGREGATION; VALIDATION PROCESS; BLOOD; DRUG EFFECT; FEMALE; HEART INFARCTION; MALE; SENSITIVITY AND SPECIFICITY; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; ASPIRIN; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPYL GALLATE; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 4444300859     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bělohlávek, J., Aschermann, M.: Kyselina acetylsalicylová a ACE inhibitory u kardiaků - fenomén pejska a kočičky? Vnitř. Lék., 2002, 48: 695-697
2. Penka, M.: Kyselina acetylsalicylová - je nám vše jasné? Vnitř. Lék., 2002, 48: 698-700
3. Petrželová, A., Stejskal, D., Prošková, J. et al.: První zkušenosti s využitím kationického propylgallátu jako induktoru agregace trombocytů v hodnocení účinnosti antiagregač ní terapie. Vnitř. Lék., 2001, 47: 747-752
4. Stejskal, D., Prošková, J., Lačňák, B. et al.: Hyperagregabilita trombocytů u pacientů s DM 2. typu -etiopatogeneza, laboratorní vyšetření, interpretace výsledků a teoretická terapeutická východiska. DMEV, 2002, sborník 1: 78
5. Stejskal, D., Prošková, J., Hamplová, A. et al.: Application of CPG as inducer of thrombocyte aggregation. Biomedical Papers, 2002, 145: 87-91
6. Stejskal, D., Lačňák, B., Prošková, J. et al.: Využití propylgallátu jako induktoru agregace trombocytů v hodnocení účinnosti antiagregač ní terapie u pacientů s akutním koronárním syndromem. Cor et Vasa, Suppl., 2002/4: 105
7. Lačňák, B., Stejskal, D., Prošková, J. et al.: Roční zkušenosti s monitorováním antiagregační terapie užitím propylgallátu jako induktoru agregace. Cor et Vasa Suppl., 2002/4: 64
8. Prošková, J., Stejskal, D.: Agregace trombocytů. FONS, 2001, 3: 17-18
9. Qi, S. P., Hu, P. R.: Effect of the esters of gallic acid on model and human blood platelet membranes studied by Fournier transform infrared spectroscopy. Sc. China B., 1993, 36: 702-709
10. Schwartz, K. A., Schwartz, D. E., Davis, J. A.: Detection and monitoring of aspirin inhibition of platelet function using the cationtic propyl gallate platelet aggregation assay. In: Abstract Book American Society of Hematology Meeting, 1998: 17-19
11. McKee, S. A., Sane, D. S., Deliaryris, E. N.: Aspirin Resistance in Cardiovascular Disease. Thromb. Haemost, 2002, 88: 711-715
12. Lam, J. Y. T.: Coronary Disease, Progression, Platelet Aggregation, and Clinical Events. Am. J. Cardiol., 1994, 73: 333
13. Assman, G.: Lipid Metabolism Disorders and Coronary Heart Disease, MMV-Meditin Verl., 1993: 281 s.
14. Cure Trial Investigators. N. Engl. J. Med., 2001, 345: 494-502
15. Rosenson, R. S.: Antiatherothrombotics Properties of Statins. JAMA, 1998, 279: 1643-1650
16. Helgason, C. M., Tortorice, K. L., Winkler, S. R. et al.: Aspirin response and failure in cerebral infarction. Stroke, 1993, 24: 345-350
17. Buchanan, M. R., Brister, S. J.: Individual variation in the effects of ASA on platelet function. Can. J. Cardiol., 1995, 11: 221-227
18. Pappas, K. M., Westengard, J. C., Bull, B. S.: Population variability in the effect of aspirin in platelet function. Arch. Pathol. Lab. Med., 1994, 118: 801-804
19. Metha, J., Metha, P.: Platelet aggregation studies in coronary artery disease. Atherosclerosis, 1978, 31: 169-175
20. Grotemeyer, K. H.: Effect of ASA in stroke patients. Thromb. Res., 1991, 63: 587-593
21. Livio, M., Del Maschio, A., Cerlleti, C.: Indomethacin prevents the long-lasting inhibitory effect of ASA on human platelet COX activity. Prostaglandins, 1982, 23: 787-796
22. Rao, G. H. R., Johnson, G. G., Reddy, K. R.: Ibuprofen protect platelet COX from irreversible inhibition by aspirin. Arteriosclerosis, 1983, 3: 383-388
23. Helgason, C. M., Bolin, K. M., Hoff, J. A.: Development as aspirin resistance in persons with previous ischemic stroke. Stroke, 1994, 25: 2331-2336
24. Colwell, J. A.: Aspirin Therapy in Diabetes Underutilized. Diab. Care, 2001, 24: 2001: 195-196
25. Rolka, D. B.: Aspirin Use among Adults with Diabetes. Diab. Care, 2001, 24: 197-201
26. Reutern, H. D.: The platelet. Science Data Suppl., 1999: 150
27. Rodak, B. F.: Diagnostic hematology. W. B. Saunders Company, 1995: 720 s.
28. Sane, D. C., McKee, S. A., Malinin, A. I. Et al.: Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am. J. Cardiol., 2002, 9: 893-895
29. Yusuf, S., Phil, D., Zhao, F. et al.: Effect of Clopidrogel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med., 2001, 345: 494-502
30. Steinhubl, S. R., Berger, P. B., Mann, J. T. et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420
31. Braunwald, E., Altman, E. M., Beasley, J. W. et al.: ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction, 2002. In: www.acc.org